Back

Nimble

Official Title

Nimble GSK 206785

Study Details

The purpose of the study is to look at an investigational (add-on) asthma medication and compare it to other available asthma medications (Fasenra® or Nucala®).

Principal Investigator

Dr. H. James Wedner

IRB Number

202102143

Eligibility

1. Participants must be at least 12 years old with a diagnosis of asthma for greater than 2 years
2. Participants must be receiving either mepolizumab 100 mg SC or benralizumab 30 mg SC (Fasenra® or Nucala®)

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back